TY - JOUR
T1 - Dextran sulfate inhibits acute Toxoplama gondii infection in pigs
AU - Kato, Kentaro
AU - Murata, Yuho
AU - Horiuchi, Noriyuki
AU - Inomata, Atsuko
AU - Terkawi, Mohamad Alaa
AU - Ishiwa, Akiko
AU - Ogawa, Yohsuke
AU - Fukumoto, Shinya
AU - Matsuhisa, Fumikazu
AU - Koyama, Kenji
N1 - Funding Information:
We thank the veterinarians and staff of the Research Institute for Animal Science in Biochemistry & Toxicology for help with the pig infection experiments. This study was supported by grants-in-aid for Young Scientists, Exploratory Research, and Scientific Research on Innovative Areas (3308 and 3407) from the Ministry of Education, Culture, Science, Sports, and Technology (MEXT) of Japan, by the Bio-oriented Technology Research Advancement Institution (BRAIN), by the Program to Disseminate Tenure Tracking System and the Adaptable & Seamless Technology Transfer Program through Target-driven R&D (A-STEP) from the Japan Science and Technology Agency (JST), by the Ito Foundation, and by the Promotion for Young Research Talent and Network from Northern Advancement Center for Science & Technology (NOASTEC).
Publisher Copyright:
© 2016 Kato et al.
PY - 2016/3/9
Y1 - 2016/3/9
N2 - Background: Toxoplasma gondii is a highly prevalent protozoan that can infect all warm-blooded animals, including humans. Its definitive hosts are Felidae and its intermediate hosts include various other mammals and birds, including pigs. It is found in the meat of livestock which is a major source of human infection. Hence the control of toxoplasmosis in pigs is important for public health. We previously showed that dextran sulfate (DS), especially DS10 (dextran sulfate MW 10 kDa), is effective against T. gondii infection both in vitro and in mice. In this study, we asked whether DS affects T. gondii infection of pigs, one of the main animal sources of toxoplasmosis transmission to humans. Methods: Fourteen-day-old male pigs (n = 10) were infected with T. gondii and then immediately treated with different doses of DS10; clinical, pathological, and immunological analyses were performed 5 days post-infection. Results: DS10 had an inhibitory effect on toxoplasmosis in pigs. Intravenous injection of DS10 prevented the symptoms of toxoplasmosis and reduced the parasite burden and inflammation induced by T. gondii infection. High-dose DS10 (500 μg per head) caused reversible hepatocellular degeneration of the liver; middle-dose DS10 (50 μg per head) was effective against toxoplasmosis in pigs without causing this side effect. Conclusions: Our data suggest that middle-dose DS10 led to minimal clinical symptoms of T. gondii infection and caused little hepatocellular degeneration in our pig model, thereby demonstrating its potential as a new treatment for toxoplasmosis. These data should be very beneficial to those interested in the control of toxoplasmosis in pigs.
AB - Background: Toxoplasma gondii is a highly prevalent protozoan that can infect all warm-blooded animals, including humans. Its definitive hosts are Felidae and its intermediate hosts include various other mammals and birds, including pigs. It is found in the meat of livestock which is a major source of human infection. Hence the control of toxoplasmosis in pigs is important for public health. We previously showed that dextran sulfate (DS), especially DS10 (dextran sulfate MW 10 kDa), is effective against T. gondii infection both in vitro and in mice. In this study, we asked whether DS affects T. gondii infection of pigs, one of the main animal sources of toxoplasmosis transmission to humans. Methods: Fourteen-day-old male pigs (n = 10) were infected with T. gondii and then immediately treated with different doses of DS10; clinical, pathological, and immunological analyses were performed 5 days post-infection. Results: DS10 had an inhibitory effect on toxoplasmosis in pigs. Intravenous injection of DS10 prevented the symptoms of toxoplasmosis and reduced the parasite burden and inflammation induced by T. gondii infection. High-dose DS10 (500 μg per head) caused reversible hepatocellular degeneration of the liver; middle-dose DS10 (50 μg per head) was effective against toxoplasmosis in pigs without causing this side effect. Conclusions: Our data suggest that middle-dose DS10 led to minimal clinical symptoms of T. gondii infection and caused little hepatocellular degeneration in our pig model, thereby demonstrating its potential as a new treatment for toxoplasmosis. These data should be very beneficial to those interested in the control of toxoplasmosis in pigs.
KW - Dextran sulfate
KW - Intermediate host
KW - Pig
KW - Public health
KW - Toxoplasma gondii
UR - http://www.scopus.com/inward/record.url?scp=84960352635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960352635&partnerID=8YFLogxK
U2 - 10.1186/s13071-016-1421-9
DO - 10.1186/s13071-016-1421-9
M3 - Article
C2 - 26956033
AN - SCOPUS:84960352635
SN - 1756-3305
VL - 9
JO - Parasites and Vectors
JF - Parasites and Vectors
IS - 1
M1 - 134
ER -